Unexpected inhibitory regulation of glutamate release from rat cerebrocortical nerve terminals by presynaptic 5-hydroxytryptamine-2A receptors

J Neurosci Res. 2006 Nov 15;84(7):1528-42. doi: 10.1002/jnr.21060.

Abstract

Presynaptic 5-HT(2A) receptor modulation of glutamate release from rat cerebrocortical nerve terminals (synaptosomes) was investigated by using the 5-HT(2A/2C) receptor agonist (+/-)-1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI). DOI potently inhibited 4-aminopyridine (4AP)-evoked glutamate release. Involvement of presynaptic 5-HT(2A) receptors in this modulation of 4AP-evoked release was confirmed by blockade of the DOI-mediated inhibition by the 5-HT(2A) receptor antagonist ketanserin but not by the 5-HT(2C) receptor antagonist RS102221. Inhibition of glutamate release by DOI was associated with a reduction of 4AP-evoked depolarization and downstream elevation of cytoplasmic free calcium concentration ([Ca(2+)](C)) mediated via P/Q- and N-type voltage-dependent Ca(2+) channels (VDCCs). In contrast to the DOI effect on 4AP-evoked release, the agonist had no effect on high external [K(+)] (30 mM)-induced (KCl) stimulation of VDCCs or glutamate release. Likewise, release mediated by direct Ca(2+) entry with Ca(2+) ionophore (ionomycin) or by hypertonic sucrose was unaffected by DOI. Mechanistically, DOI modulation of 4AP-evoked glutamate release appeared to involve a phospholipase C/protein kinase C signaling cascade, insofar as pretreatment of synaptosomes with the phospholipase C inhibitor U73122 or protein kinase C inhibitors Ro320432 or GF109203X all effectively occluded the inhibitory effect of the agonist. Together, these results suggest that presynaptic 5-HT(2A) receptors present on glutamatergic terminals effect an unexpected depression of glutamate release by negatively modulating nerve terminal excitability and downstream VDCC activation through a signaling cascade involving phospholipase C/protein kinase C. These observations invoke presynaptic inhibitory 5-HT(2A) receptor function as a potential target for drugs to mitigate the effects of excessive glutamatergic transmission.

Publication types

  • Comparative Study

MeSH terms

  • Amphetamines / pharmacology
  • Animals
  • Calcium / metabolism
  • Calcium Channel Blockers / pharmacology
  • Cerebral Cortex / cytology*
  • Dicarboxylic Acids / pharmacology
  • Drug Interactions
  • Enzyme Inhibitors / pharmacology
  • Glutamic Acid / metabolism*
  • Ketanserin / pharmacology
  • Male
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Neural Inhibition / drug effects
  • Neural Inhibition / physiology*
  • Neurotransmitter Uptake Inhibitors / pharmacology
  • Presynaptic Terminals / drug effects
  • Presynaptic Terminals / metabolism*
  • Pyrrolidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Serotonin, 5-HT2A / physiology*
  • Serotonin Antagonists / pharmacology
  • Serotonin Receptor Agonists / pharmacology
  • Spiro Compounds / pharmacology
  • Sulfonamides / pharmacology
  • Synaptosomes / drug effects
  • Synaptosomes / metabolism
  • Time Factors
  • omega-Agatoxin IVA / pharmacology
  • omega-Conotoxin GVIA / pharmacology

Substances

  • 8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione
  • Amphetamines
  • Calcium Channel Blockers
  • Dicarboxylic Acids
  • Enzyme Inhibitors
  • Neurotransmitter Uptake Inhibitors
  • Pyrrolidines
  • Receptor, Serotonin, 5-HT2A
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • Spiro Compounds
  • Sulfonamides
  • omega-Agatoxin IVA
  • Glutamic Acid
  • omega-Conotoxin GVIA
  • Ketanserin
  • pyrrolidine-2,4-dicarboxylic acid
  • 4-iodo-2,5-dimethoxyphenylisopropylamine
  • Calcium